How has Bioventus's preferred stock, par or stated value per share changed year-over-year?

Bioventus's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.

What is the long-term trend for Bioventus's preferred stock, par or stated value per share?

Over 4 years (2021 to 2025), Bioventus's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.

Bioventus BVS Preferred Stock, Par or Stated Value Per Share

Preferred Stock, Par or Stated Value Per Share at other companies

ArtivionAORT

——

Envista Holdings CorporationNVST

——

IAR

Integra LifeSciencesIART

——

Avanos MedicalAVNS

——

Collegium Pharmaceutical, Inc.COLL

——

SI-BONE, Inc.SIBN

——

Other financials

Income statement

See full

Revenue$132.1M+6.6%

Gross profit$90.8M+9.3%

Operating income$8.4M+72.8%

Net income$3.1M+218%

EPS (diluted)$0.04+200%

Balance sheet

See full

Cash & equivalents$35.8M+57.2%

Total debt$288.4M-21.2%

Total equity$188.9M+27.5%

Total assets$650.5M-5.9%

Cash flow

See full

Operating cash flow$8.9M+146%

CapEx$574.0K-30.5%

Free cash flow$8.4M+141%

Valuation

See full

Market cap$659.19M+51.7%

Enterprise value$911.76M+17.2%

P/E23.1×—

P/S1.1×+0.4×

Profitability

See full

Gross margin68.7%+1.2pp

Operating margin10%—

Net margin4.9%+3.2pp

FCF margin17.5%+13.2pp

Returns & leverage

See full

Return on equity16.9%+10.9pp

Debt / equity1.5×-0.9×

Current ratio1.7×+0.3×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.

The official record: Bioventus’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bioventus's preferred stock, par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Bioventus's preferred stock, par or stated value per share?: Bioventus (BVS) reported preferred stock, par or stated value per share of $0 in Q1 2026.
How has Bioventus's preferred stock, par or stated value per share changed year-over-year?: Bioventus's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0 to $0.
What is the long-term trend for Bioventus's preferred stock, par or stated value per share?: Over 4 years (2021 to 2025), Bioventus's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.